Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Updated Warfarin Label Notes Genetics’ Impact On Dosing, But Avoids Recommending Test

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA adds pharmacogenetic information to warfarin label, says more specific recommendations on genetic testing and appropriate dosing await further studies.

You may also be interested in...

FDA Updates Codeine Labeling With Risk Of Morphine Overdose In Breastfed Newborns

Public Health Advisory focuses on risk of morphine overdose in nursing mothers who are “ultra-rapid” metabolizers of codeine.

Rx Misbranding Penalties Should Be Stronger To Stop Counterfeiting, FDA Says

Industry also seems supportive of the idea, while Pew touts the power of the power of track-and-trace as a deterrent.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts